ğŸ“‘ Timeline Outline â€” GLP-1s vs. Fentanyl Crisis

2005
	â€¢	GLP-1: Exenatide (Byetta) approved â€” first GLP-1 receptor agonist.
	â€¢	Fentanyl: First wave of â€œfentanyl-relatedâ€ deaths reported, tied to diverted medical supplies.

â¸»

2010
	â€¢	GLP-1: Liraglutide (Victoza) approved (daily injection).
	â€¢	Fentanyl: Overdose data still dominated by prescription opioids, but fentanyl incidents noted as â€œemerging threat.â€

â¸»

2013â€“2014
	â€¢	GLP-1: Market expansion, wider uptake of Victoza.
	â€¢	Fentanyl: Sharp spike in illicit fentanyl imports; heroin increasingly cut with fentanyl.
	â€¢	Crisis language begins: â€œThird waveâ€ of opioid epidemic described.

â¸»

2014â€“2017
	â€¢	GLP-1:
	â€¢	Dulaglutide (Trulicity) approved (2014, weekly).
	â€¢	Semaglutide (Ozempic) approved (2017, weekly).
	â€¢	Fentanyl:
	â€¢	2015â€“2016: CDC warns of â€œfentanyl epidemic.â€
	â€¢	2016â€“2017: Fentanyl overtakes heroin in reported overdose deaths.
	â€¢	Overlap: â€œFentanyl panicâ€ explodes just as longer-acting GLP-1s come online.

â¸»

2018â€“2020
	â€¢	GLP-1:
	â€¢	Semaglutide rollout accelerates.
	â€¢	Off-label use for weight loss spreads.
	â€¢	Fentanyl:
	â€¢	Deaths attributed to fentanyl surpass those from prescription opioids and heroin combined.
	â€¢	â€œFentanyl crisisâ€ becomes dominant public narrative.

â¸»

2021â€“Present
	â€¢	GLP-1:
	â€¢	Wegovy (semaglutide for weight loss) approved (2021).
	â€¢	Mounjaro (tirzepatide, GLP-1/GIP dual agonist) approved (2022).
	â€¢	Cultural explosion of â€œOzempicâ€ in media.
	â€¢	Fentanyl:
	â€¢	CDC: fentanyl now the leading cause of drug overdose deaths in the U.S.
	â€¢	Deaths continue rising even where opioid supply hasnâ€™t.

â¸»

Continuity-Theater Overlay
	â€¢	2005â€“Present: Every major expansion of GLP-1 availability coincides with a new â€œsurgeâ€ in fentanyl deaths.
	â€¢	Narrative payoff: GLP-1 side-effects and pharmacokinetic sabotage plausibly laundered through the fentanyl label.
